Viridian (VRDN) | Stock Overview & Key Data
Viridian Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $2,247.75 on June 16, 2014
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Financial Highlights
Profitability
Returns and Earnings
Growth
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Viridian VRDN | 1.20B Small-cap | 13.66% | 6.93% | 34.89% | -24.01% | -19.59% | 27.19% | 27.29% | 11.37% |
| Vertex VRTX | 114.06B Large-cap | 3.19% | 2.97% | -3.19% | 12.51% | 13.22% | -3.15% | 56.18% | 56.09% |
| Regeneron REGN | 55.27B Large-cap | 2.50% | 3.96% | -6.05% | -26.32% | -24.76% | -47.08% | -11.94% | -11.84% |
| Vera Therapeutics VERA | 1.38B Small-cap | -2.50% | 3.52% | 15.20% | -45.44% | -45.57% | -32.64% | 63.38% | 108.70% |
| Immunocore Holdings IMCR | 1.56B Small-cap | 3.28% | -10.15% | 23.33% | 5.16% | 8.69% | -10.68% | -26.05% | -23.56% |
| Agios AGIO | 1.93B Small-cap | 5.86% | 4.60% | 35.95% | 0.26% | 10.58% | -15.43% | 38.73% | -31.81% |
Ownership & Short Interest
Viridian Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Viridian would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
In the last 52 weeks, Viridian reached a high of $27.20 (on November 12, 2024) and a low of $9.90 (on April 9, 2025).
Curious about Viridian's size and valuation? Its market capitalization stands at 1.20B. When it comes to valuation, the P/E ratio (trailing twelve months) is -4.78, and the forward P/E (looking ahead) is -3.51.
As for dividends, Viridian isn't currently offering a significant yield, or that specific data isn't available right now.
When looking at Viridian, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX114.06B Healthcare Biotechnology -3.15% 56.18% Regeneron
REGN55.27B Healthcare Biotechnology -47.08% -11.94% Vera Therapeutics
VERA1.38B Healthcare Biotechnology -32.64% 63.38% Immunocore Holdings
IMCR1.56B Healthcare Biotechnology -10.68% -26.05% Agios
AGIO1.93B Healthcare Biotechnology -15.43% 38.73% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
To get a sense of Viridian's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -51.95%, the Debt to Equity ratio from the most recent quarter is 3.82, and its Gross Profit Margin stands at N/A.
Looking at Viridian's growth, its revenue over the trailing twelve months (TTM) was $302K. Compared to the same quarter last year (YoY), quarterly revenue grew by 0.00%, and quarterly earnings saw a YoY growth of 0.00%.
Wondering who owns Viridian stock? Company insiders (like executives and directors) hold about 0.16% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 114.23%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.